Generation of pluripotent stem cells without the use of genetic material

Laboratory Investigation

Volumn 95, Issue 1, 2015, Pages 26-42

  Higuchi, Akon ^a,b   Ling, Qing Dong ^a,c   Kumar, S Suresh ^d   Munusamy, Murugan A ^b   Alarfaj, Abdullah A ^b   Chang, Yung ^e   Kao, Shih Hsuan ^a   Lin, Ke Chen ^a   Wang, Han Chow ^f   Umezawa, Akihiro ^g  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d Department of Medical Microbiology and Parasitology Universities Putra Malaysia   (Malaysia)

^e CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^f Department of Obstetrics and Gynecology   (Taiwan)

^g NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE;

CELL CULTURE; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; IN VITRO STUDY; LARGE SCALE PRODUCTION; ONCOGENE C MYC; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SOMATIC CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CYTOLOGY; GENETIC PROCEDURES; MOUSE;

ANIMALS; GENETIC TECHNIQUES; HUMANS; MICE; PLURIPOTENT STEM CELLS;

EID: 84920086707     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.132     Document Type: Review

References (100)

1. Fujimoto M, Hayashi H, Takagi Y, et al. Transplantation of telencephalic neural progenitors induced from embryonic stem cells into subacute phase of focal cerebral ischemia. Lab Invest 2012;92:522-531.
2. Callahan LA, Xie S, Barker IA, et al. Directed differentiation and neurite extension of mouse embryonic stem cell on aligned poly(lactide) nanofibers functionalized with YIGSR peptide. Biomaterials 2013;34: 9089-9095.
3. Higuchi A, Ling QD, Kumar SS, et al. Design of polymeric materials for culturing human pluripotent stem cells: progress toward feeder-free and xeno-free culturing. Prog Polym Sci 2014;39:1348-1374.
4. Gokhale PJ, Andrews PW. Human embryonic stem cells: 10 years on. Lab Invest 2009;89:259-262.
5. Hankowski KE, Hamazaki T, Umezawa A, et al. Induced pluripotent stem cells as a next-generation biomedical interface. Lab Invest 2011;91:972-977.
6. de Wert G, Mummery C. Human embryonic stem cells: research, ethics and policy. Hum Reprod 2003;18:672-682.
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
8. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131: 861-872.
9. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317.
10. Aoi T, Yae K, Nakagawa M, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008;321:699-702.
11. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920.
12. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-106.
13. Kim JB, Greber B, Arauzo-Bravo MJ, et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009;461:649-653.
14. Xie M, Cao N, Ding S. Small molecules for cell reprogramming and heart repair: Progress and perspective. Acs Chem Biol 2014;9:34-44.
15. Li Y, Zhang Q, Yin X, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res 2011;21: 196-204.
16. Kim JB, Sebastiano V, Wu GM, et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009;136:411-419.
17. Hou PP, Li YQ, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013;341:651-654.
18. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-476.
19. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-384.
20. Li WL, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci 2010;31:36-45.
21. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007;1:39-49.
22. Cohen DE, Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 2011;12:243-252.
23. Chun YS, Chaudhari P, Jang YY. Applications of patient-specific induced pluripotent stem cells; Focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci 2010;6:796-805.
24. Nishimura K, Sano M, Ohtaka M, et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011;286:4760-4771.
25. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-949.
26. Zhou WB, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27: 2667-2674.
27. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-770.
28. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322: 949-953.
29. Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC. Develop Biol 2010;10:81.
30. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801.
31. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458: 771-775.
32. MacArthur CC, Fontes A, Ravinder N, et al. Generation of humaninduced pluripotent stem cells by a nonintegrating RNA sendai virus vector in feeder-free or xeno-free conditions. Stem Cells Int 2012; 2012:564612.
33. Chou BK, Mali P, Huang XS, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011;21:518-529.
34. Cheng L, Hansen NF, Zhao L, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012;10:337-344.
35. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008;14: 2115-2124.
36. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patientderived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-977.
37. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-630.
38. Firestone AJ, Chen JK. Controlling destiny through chemistry: Smallmolecule regulators of cell fate. Acs Chem Biol 2010;5:15-34.
39. Wu YL, Pandian GN, Ding YP, et al. Clinical grade iPS cells: Need for versatile small molecules and optimal cell sources. Chem Biol 2013;20:1311-1322.
40. Zhu S, Wei W, Ding S. Chemical strategies for stem cell biology and regenerative medicine. Annu Rev Biomed Eng 2011;13:73-90.
41. Feng B, Ng JH, Heng JCD, et al. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009;4:301-312.
42. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008;26:795-797.
43. Zhu SY, Li WL, Zhou HY, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010;7:651-655.
44. Zhang XZ. Modulation of embryonic stem cell fate and somatic cell reprogramming by small molecules. Reprod Biomed Online 2010;21: 26-36.
45. Anastasia L, Pelissero G, Venerando B, et al. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ 2010;17:1230-1237.
46. Li WL, Jiang K, Ding S. Concise review: A chemical approach to control cell fate and function. Stem Cells 2012;30:61-68.
47. Lu JY, Kong XQ, Luo C, et al. Application of epigenome-modifying small molecules in induced pluripotent stem cells. Med Res Rev 2013;33:790-822.
48. Lukaszewicz AI, McMillan MK, Kahn M. Small molecules and stem cells. Potency and lineage commitment: The new quest for the fountain of youth. J Med Chem 2010;53:3439-3453.
49. Groß B, Sgodda M, Rasche M, et al. Improved generation of patientspecific induced pluripotent stem cells using a chemically-defined and matrigel-based approach. Curr Mol Med 2013;13:765-776.
50. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotech 2002;13:52-56.
51. Michiue H, Tomizawa K, Wei FY, et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 2005;280:8285-8289.
52. Inoue M, Tomizawa K, Matsushita M, et al. p53 protein transduction therapy: Successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol 2006;49:161-168.
53. Lafevre-Bernt M, Wu S, Lin X. Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells. Mol Cancer Ther 2008;7:1420-1429.
54. Ziegler A, Nervi P, Durrenberger M, et al. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry 2005;44:138-148.
55. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. Aaps J 2009;11:13-22.
56. Jin J, Kwon YW, Paek JS, et al. Analysis of differential proteomes of induced pluripotent stem cells by protein-based reprogramming of fibroblasts. J Proteome Res 2011;10:977-989.
57. Zhu XQ, Pan XH, Wang WB, et al. Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. Biomaterials 2010;31:2779-2787.
58. Zheng Z, Jian J, Zhang XL, et al. Reprogramming of human fibroblasts into multipotent cells with a single ECM proteoglycan, fibromodulin. Biomaterials 2012;33:5821-5831.
59. Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010;116:386-395.
60. Rajasingh J, Lambers E, Hamada H, et al. Cell-free embryonic stem cell extract-mediated derivation of multipotent stem cells from NIH3T3 fibroblasts for functional and anatomical ischemic tissue repair. Circ. Res. 2008;102:E107-E117.
61. Rhee YH, Ko JY, Chang MY, et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clinical Invest 2011;121:2326-2335.
62. Vezoli J. Recombinant proteins to induce pluripotent stem cells: Promises for a safer and thriving step toward clinical trials. Movement Disord 2011;26:1409-1409.
63. Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008;3:568-574.
64. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009;5:353-357.
65. Jung DW, Kim WH, Williams DR. Reprogram or reboot: Small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming. Acs Chem Biol 2014;9:80-95.
66. Sterneckert J, Hoing S, Scholer HR. Concise review: Oct4 and more: The reprogramming expressway. Stem Cells 2012;30:15-21.
67. Shi Y, Do JT, Desponts C, et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;2:525-528.
68. Pasha Z, Haider HK, Ashraf M. Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PLoS One 2011;6:e23667.
69. Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009;5:491-503.
70. Wang Q, Xu XX, Li J, et al. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res 2011;21:1424-1435.
71. Li W, Zhou H, Abujarour R, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009;27:2992-3000.
72. Staerk J, Lyssiotis CA, Medeiro LA, et al. Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. Angew Chem Int Edit 2011;50:5733-5735.
73. Yuan X, Wan HF, Zhao XY, et al. Brief report: Combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells 2011;29:549-553.
74. Moon JH, Heo JS, Kim JS, et al. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Cell Res 2011;21:1305-1315.
75. Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009;106:8912-8917.
76. Allsopp TE, Bunnage ME, Fish PV. Small molecule modulation of stem cells in regenerative medicine: recent applications and future direction. Medchemcomm 2010;1:16-29.
77. Mikkelsen TS, Hanna J, Zhang XL, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008;454:49-55.
78. Lee MG, Wynder C, Schmidt DM, et al. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006;13:563-567.
79. Mali P, Chou BK, Yen J, et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-Associated genes. Stem Cells 2010;28:713-720.
80. Liang GY, Taranova O, Xia K, et al. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem 2010;285:25516-25521.
81. Yoshida Y, Takahashi K, Okita K, et al. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009;5:237-241.
82. Lee J, Xia Y, Son MY, et al. A novel small molecule facilitates the reprogramming of human somatic cells into a pluripotent state and supports the maintenance of an undifferentiated state of human pluripotent stem cells. Angew Chem Int Edit 2012;51:12509-12513.
83. Chen TT, Shen L, Yu J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011;10:908-911.
84. Li ZH, Rana TM. A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation. Nat Commun 2012;3:2059.
85. Giorgetti A, Montserrat N, Rodriguez-Piza I, et al. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc 2010;5:811-820.
86. Page RL, Ambady S, Holmes WF, et al. Induction of stem cell gene expression in adult human fibroblasts without transgenes. Cloning Stem Cells 2009;11:417-426.
87. Kim JB, Zaehres H, Wu GM, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008;454:646-650.
88. Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008;6:e253.
89. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269-1275.
90. Szablowska-Gadomska I, Sypecka J, Zayat V, et al. Treatment with small molecules is an important milestone towards the induction of pluripotency in neural stem cells derived from human cord blood. Acta Neurobiol Exp 2012;72:337-350.
91. Higuchi A, Ling QD, Chang Y, et al. Physical cues of biomaterials guide stem cell differentiation fate. Chem Rev 2013;113:3297-3328.
92. Masip M, Veiga A, Belmonte JCI, et al. Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. Mol Hum Reprod 2010;16:856-868.
93. Efe JA, Ding S. The evolving biology of small molecules: controlling cell fate and identity. Philos T R Soc B 2011;366:2208-2221.
94. Roessler R, Boddeke E, Copray S. Induced pluripotent stem cell technology and direct conversion: New possibilities to study and treat Parkinson's disease. Stem Cell Rev Rep 2013;9:505-513.
95. Masuda S, Wu J, Hishida T, et al. Chemically induced pluripotent stem cells (CiPSCs): a transgene-free approach.. J Mol Cell Biol 2013;5: 354-355.
96. Han DW, Tapia N, Hermann A, et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012;10:465-472.
97. Lujan E, Chanda S, Ahlenius H, et al. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci USA 2012;109:2527-2532.
98. Thier M, Worsdorfer P, Lakes YB, et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 2012;10:473-479.
99. Tapia N, Han DW, Scholer HR. Restoring stem cell function in aged tissues by direct reprogramming? Cell Stem Cell 2012;10:653-656.
100. Li WL, Jiang K, Wei WG, et al. Chemical approaches to studying stem cell biology. Cell Res 2013;23:81-91.